Siranomics Closes $105 Million Funding from China Investors; Plans IPO
publication date: Oct 23, 2020
Sirnaomics, a US-China company developing RNAi therapeutics, closed a $105 million Series D round from China investors. The company is developing a portfolio of novel RNAi therapeutics that address a range of diseases including various cancers, fibrosis diseases, metabolic diseases and viral infections. Earlier this year, it announced positive interim results from a Phase IIa study of STP705 for Cutaneous Squamous Cell Carcinoma in-situ. Siranomics, which plans to conduct an IPO in the near future, is headquartered in Maryland, with China operations in Suzhou and Guangzhou. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.